All In Biotech

Drug Trial Radar · NCT05384938

FAsenra Safety Trial in India

A Postmarketing, Phase 4, Multicentre, Prospective, Single-arm Study to Assess the Safety of Fasenra® (Benralizumab) in Adult Patients of Severe Asthma With Eosinophilic Phenotype in India.

Last checked: Nov 20, 2026Latest source record: Dec 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

139

Actual

Start

Nov 19, 2021

Primary completion

Jul 1, 2023

Study completion Jul 1, 2023

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Benralizumab is a humanised, afucosylated, monoclonal antibody that binds specifically to the human interlukin-5 (IL-5) receptor alpha subunit (IL-5Rα) of target cells such as eosinophils and basophils (Takatsu et al, 1994; Toba et al, 1999; Pelaia et al, 2020). Benralizumab was generally well tolerated by patients in clinical trials, with no apparent safety concerns. This study shall be conducted at 10 centers across India. The primary outcome measures will be * Percentage of AEs a, SAEs, and TEAEs * Nature, incidence, and severity of AEs including unexpected adverse drug reactions * Percentage of patients with AEs that lead to study treatment discontinuations.

Conditions

  • In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India

Interventions

  • BenralizumabBiological

    Prospective, Single-arm Study to Assess the Safety of Fasenra® (Benralizumab) in Adult Patients of Severe Asthma with Eosinophilic Phenotype in India

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants With Adverse Events (AEs), Serious AEs, and Treatment-emergent AEsTime frame: From study treatment to follow-up (up to 24 weeks)
  2. Severity of AEsTime frame: From study treatment to follow-up (up to 24 weeks)
  3. Participants With AEs That Led to Study Treatment Discontinuations or ModificationsTime frame: From study treatment to follow-up (up to 24 weeks)

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Bengaluru, India

  • Research Site

    Chennai, India

  • Research Site

    Delhi, India

  • Research Site

    Hyderabad, India

  • Research Site

    Jaipur, India

  • Research Site

    Jodhpur, India

  • Research Site

    Lucknow, India

  • Research Site

    Mumbai, India

  • Research Site

    New Delhi, India

  • Research Site

    Noida, India

  • Research Site

    Noida, India

  • Research Site

    Noida, India

  • Research Site

    Visakhapatnam, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.